Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Reduction of global H3K27me3 enhances HER2/ErbB2 targeted therapy

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis

Rheb1-independent activation of mTORC1 in mammary tumors occurs through activating mutations in mTOR

Abstract B007: c-Src and PRC2 activity in ErbB2-driven mammary tumorigenesis and acquired resistance to ErbB2-targeted therapy

A Tri-Droplet Liquid Structure for Highly Efficient Intracellular Delivery in Primary Mammalian Cells Using Digital Microfluidics

The role of SHIP1 in modulating disease severity in the K/BxN serum transfer model of rheumatoid arthritis

A Tri‐Droplet Liquid Structure for Highly Efficient Intracellular Delivery in Primary Mammalian Cells Using Digital Microfluidics (Adv. Mater. Technol. 21/2023)

Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways

Abstract B46: Targeting EZH2 reactivates a breast cancer subtype-specific antimetastatic transcriptional program

Genetic and pharmacological exploration of the methyltransferase Ezh2 in different breast cancer subtypes

Abstract A15: Using genetic and pharmacological methods to explore role of the methyltransferase Ezh2 in mouse mammary tumorigenesis

Analysis of Tie2 function in mast cells

Endoglycan is a CD34-related marker of marginal zone B cells and is upregulated by TLR ligands (94.7)